Navigation Links
Enzymatics Reports Latest Growth Figures; Confirms Massachusetts' Emerging Role as Leading Bio-manufacturing Center
Date:6/9/2011

BEVERLY, Mass., June 9, 2011 /PRNewswire/ -- Enzymatics, Inc. announced today that the company, whose revenues have doubled every year since 2007, is forecasting triple the revenue in 2011 over 2010 figures.  It is also expanding its corporate offices and manufacturing facility in Beverly, Massachusetts.  The move is one of several significant milestones for the five year-old, privately held firm that supplies biological reagents as well as bio-processing consulting services to the international scientific and healthcare markets.  It also demonstrates that Massachusetts is no longer just a biotech R&D nursery and is quickly becoming an international center for biotech manufacturing.

Enzymatics' proprietary manufacturing process produces commercial quantities of enzymes measurably superior in purity and consistency to those created in small batches for the research field — but at a much lower cost.  The timing couldn't be better as national and international bioscience and pharmaceutical companies rush to create genomic diagnostics and bio-ceutical drug therapies for mass-market distribution.  Reagents are critical components of these products and in Enzymatics, their manufacturers have found an ideal partner supplier that can scale up to meet large production levels while exceeding purity standards and keeping costs down.  

"Our growth and expansion are a great confirmation that we had the right vision at exactly the right time," states Enzymatics Co-Founder and President Chris Benoit.  "It's been an incredible ride that's about to get even more exciting as we expand our presence in larger, international markets."  The company is currently establishing its first full-service overseas office in Europe. Enzymatics now supports a full time staff of more than 50 and is actively looking to fill an additional 15 positions.  

When asked to share his own perspective on the company's progress, Co-Founder and CEO Stephen Picone replied, "You can sense the future here...We're perfecting new manufacturing technologies built on our core competencies.  And the key collaborations we're setting up will lay the groundwork for the development of novel enzymes.  Both of these initiatives will add a great deal of value to our customer's businesses."

ABOUT ENZYMATICS:  Enzymatics is a leading biotechnology and biosciences manufacturing company that delivers ISO 13485-compliant enzymes of unrivaled purity, consistency, and value to the healthcare and bioscience industries.  For more information, please visit www.enzymatics.com.

Lisa Lazarczyk
781-646-0667 or lisa@lazpr.com


'/>"/>
SOURCE Enzymatics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales
2. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
3. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
4. Cyberonics Reports Record Fiscal 2011 Results and Provides Fiscal 2012 Guidance
5. China Medical Technologies Reports Fourth Fiscal Quarter and Full Fiscal Year Financial Results
6. Encision Reports Profitable Fourth Quarter and Fiscal Year 2011 Results
7. Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011
8. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
9. China Nepstar Chain Drugstore Reports First Quarter 2011 Financial Results
10. HealthWarehouse.com Reports 82% Quarter-Over-Quarter Revenue Growth in the First Quarter 2011
11. Omeros Reports Allowance of Additional Patent for Arthroscopic Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... the Centers for Disease Control and Prevention (CDC), influenza vaccination should ... helping communities across Massachusetts , Connecticut ... shots through the end of the month. *Some exclusions apply ... ... is by the end of October, according to the Centers for Disease ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... , ... October 12, 2017 , ... On Saturday, October ... treadmill relay – Miles by Moonlight to raise money for the American Heart Association ... more. , Teams will work together to keep their treadmills moving for 5 ...
(Date:10/12/2017)... ... 2017 , ... Vohra Chief Medical Officer Dr. Shark Bird, ... nursing facility medical directors and other clinicians at various events in October. His ... many of these conferences we get to educate other physicians, facility nurses, corporate ...
Breaking Medicine News(10 mins):